ID: arginine
Aliases: L-arginine
Type: compound
Route/form: oral supplement unless otherwise specified
Status: supplement
Evidence level: preclinical
Best data tier: direct preclinical; adjacent human controlled/review
Support scope: human, non-human/mechanistic
Source types: meta_analysis, preclinical
Linked sources: 3
Broad outcomes: Brain / mood / sleep, Cardiovascular / lipids / blood pressure
Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.
Targets / mechanism
- nitric oxide precursor
- amyloid-beta pathology model
Optimization domains
- cognitive support
- alzheimers disease models
- vascular function
- supplement
Research basis
- A 2025 animal-model paper reports oral arginine suppression of amyloid-beta pathology.
- Arginine is already a common supplement, so disease-model claims are likely to circulate.
Limits, risks, and missing evidence
- Alzheimer's model effects should not be treated as cognitive prevention or treatment in humans.
- NO/vascular effects can be context dependent and interact with cardiovascular medications.
Risk flags
- preclinical only for abeta claim
- supplement
- cardiovascular interactions
- limited clinical translation
- adjacent human evidence
Linked papers, labels, and reviews
- Oral administration of arginine suppresses Abeta pathology in animal models of Alzheimer's disease
preclinical / pubmed_arginine_abeta_2025
Mouse and Drosophila Alzheimer's disease model source. - The Potential Role of Arginine Supplements on Erectile Dysfunction: A Systematic Review and Meta-Analysis
meta_analysis / pubmed_arginine_ed_meta_2019
Human ED supplement meta-analysis; provides NO/endothelial clinical context separate from the Abeta animal model claim. - Effect of L-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-analysis
meta_analysis / pubmed_arginine_bp_meta_2022
Human RCT meta-analysis for blood pressure; useful vascular endpoint context for arginine/NO claims.